SIG Corner Editor: Hana Abou Zeid
Chair: Julian Garcia Feijoo
Co-chair: Keith Barton
Preserflo MicroShunt: Minimizing Corneal Endothelial Cell Impact with Proper Positioning
Dr Laura Morales
Preserflo MicroShunt is an effective glaucoma treatment with a favourable safety profile and it has been associated with variable impacts on corneal endothelial cells(1).
Recent studies indicate that endothelial cell density (ECD) may experience minimal changes post-implantation. Over a one-year period, ECD decreased by approximately -5.2% after Preserflo microshunt (2). After two years, a higher percentage change of ECD from baseline was observed after trabeculectomy (-9.6%) than after Preserflo microshunt (-7.7%) (2).
Maintaining a sufficient distance between the tube and the corneal endothelium is crucial to minimize ECD loss, emphasizing the importance of correct surgical technique and positioning. Distances greater than 600 microns significantly reduce the risk of ECD loss, nearing zero (3).
MicroShunt vs Trabeculectomy: Interim Safety Observations From an Ongoing Open Label Extension Study in Patients With Primary Open-Angle Glaucoma.World Glaucoma Congress, 2023. Santen. Web. https://www.santen.eu.
SURGERY SIG MEETINGS ACTIVITIES AND FUTURE ACTIONS
In the last two years we have been working to update the group and its objectives within the framework of the EGS.